Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder
Makaleler > Tam Makale · 2015
Yazarlar: Nazlı Burcu ÖZBARAN, Sezen KÖSE, O YUZUGULDU, B ATAR, C AYDIN
The World Journal of Biological Psychiatry, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2015, cilt 16, ss 619-624
DOI: 10.3109/15622975.2015.1051109
Özet
OBJECTIVES: Pharmacological treatment of attention deficit hyperactivity disorder (ADHD) includes stimulant and non-stimulant medications. Our purpose in this study is to investigate efficacy, safety and tolerability of combined methylphenidate and atomoxetine pharmacotherapy. METHODS: We included 12 patients of the 824 patients with ADHD using methylphenidate and atomoxetine combined therapy between the years 2010 and 2014. Kiddie-SADS, Turgay DSM-IV Based Child and Adolescent Behavior Disorders Screening and Rating Scale, Child Behavior Checklist, Clinic Global Impression Scale Severity and Impression (CGIS-S-I) scales were used. RESULTS: Patients were between the ages of 7 and 17 years. Before combined pharmacotherapy the CGIS-S score mean was 5.08. Mean CGIS-S score after the combined pharmacotherapy was 3.08 (P = 0.03; -2,980). The most common side effects were irritability (n = 5, 41.6%), appetite reduction (n = 3, 25%), palpitations (n = 2, 16.7%), headache (n = 1, 8.3%). CONCLUSIONS: Nine of these 12 patients showed significant improvement in their symptoms, combined therapy enhanced the effectiveness of monotherapy.